Xbrane Hails FDA Win On ‘Streamlined’ Nivolumab Trial Program

FDA And EMA Agreement On Opdivo Biosimilar Cuts Costs And Timelines As Firm Seeks Partner

 
• By Dave Wallace
  
Wooden Blocks Spelling Cost With Arrows Pointing Down
Xbrane’s plan for a single trial will reduce development costs • Source: Shutterstock

More from Biosimilars

More from Products